Multiple Myeloma: An In-depth Review of the Historical and Pathogenetic Processes
Asian Hematology Research Journal,
Myeloma is a plasma cell disorder which occurs with varying prevalence across different populations across the globe. Knowledge of the disease pathogenesis as well as its diagnosis and treatment has evolved over the years. The mutations that underlying the progression from benign gammopathy to overt clinical carcinomatosis has been studied extensively and has provided targets for immunotherapy. The causes of variations in incidence of multiple myeloma across different regional and socio-culturally diverse groups has been proposed to be multi-factorial, as denoted by the plethora of mutations driving disease progression in these groups. The sequence of mutation – primary and secondary events, in oncogenesis have been described though no apparent environmental or infective organism has been consistently link with myeloma. The impact of interleukin 6 and RANKL in the severity of myeloma bone disease has been observed to high and offers both contemporary and future therapeutic targets. This review is targeted at providing in-depth insight into the historical events as well as the molecular basis of this disease.
- plasma cell
How to Cite
Siegel RL, Miller KD, Sauer AG, et al. Colorectal cancer statistics, 2020. CA. Cancer J. Clin. 2020;70(3):145–164.
Fleischer R. Ueber das Vorkommen des sogenannten Bence Jones’schen Eiweisskörpers im normalen Knochenmark. Arch. Für Pathol. Anat. Physiol. Für Klin. Med. 1880;80(3):482–489.
Geschickter CF. Multiple Myeloma as a Single Lesion. Ann. Surg. 1930;92(3):425–433.
Korngold L, Lipari R. Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gammaglobulin and multiple-myeloma serum proteins. Cancer. 1956; 9(2):262–272.
Edelman GM, Gally JA. The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins. J. Exp. Med. 1962;116:207–227.
Kyle RA. Multiple Myeloma: How Did It Begin? Mayo Clin. Proc. 1994;69(7):680–683.
Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960;56:211–231.
Kyle RA. Monoclonal gammopathy of undetermined significance: Natural history in 241 cases. Am. J. Med. 1978;64(5):814–826.
Tiselius A. Electrophoresis of serum globulin. Biochem. J. 1937;31(9):1464–1477.
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854.
Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005;23(15):3412–3420.
Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin. Proc. 2007;82(3):323–341.
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015;33(26):2863–2869.
Kyle RA, Therneau TM, Rajkumar SV, et al. A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance.
Available:http://dx.doi.org/10.1056/NEJMoa01133202. 2002 Feb 21;346(8):564-9.
Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 2007;356(25):2582–2590.
Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: Redefining myeloma. Nat. Rev. Clin. Oncol. 2012;9(9):494–496.
Rajkumar SV, Larson D, Kyle RA. Diagnosis of Smoldering Multiple Myeloma. N. Engl. J. Med. 2011;365(5):474–475.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548.
Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. J. Cancer Epidemiol. 2014;2014:e437971.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136(5):E359–E386.
Echimane AK, Ahnoux AA, Adoubi I, et al. Cancer incidence in Abidjan, Ivory Coast. Cancer. 2000;89(3):653–663.
Schonfeld SJ, Erdmann F, Wiggill T, et al. Hematologic malignancies in South Africa 2000–2006: analysis of data reported to the National Cancer Registry. Cancer Med. 2016;5(4):728–738.
Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010;116(25):5501.
Greenberg AJ, Philip S, Paner A, et al. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J. 2015;5(1):e271.
Davies FE, Rawstron AC, Owen RG, Morgan GJ. Controversies surrounding the clonogenic origin of multiple myeloma. Br. J. Haematol. 2000;110(1):240–241.
Johnsen HE, Bøgsted M, Schmitz A, et al. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica. 2016;101(12):1451–1459.
Ryser JE, Vassalli P. Mouse bone marrow lymphocytes and their differentiation. J. Immunol. Baltim. Md 1950. 1974;113(3):719–728.
Brack C, Hirama M, Lenhard-Schuller R, Tonegawa S. A complete immunoglobulin gene is created by somatic recombination. Cell. 1978;15(1):1-14.
Victora GD, Nussenzweig MC. Germinal centers. Annu. Rev. Immunol. 2012;30:429–457.
Stavnezer J, Guikema JEJ, Schrader CE. Mechanism and Regulation of Class Switch Recombination. Annu. Rev. Immunol. 2008;26:261–292.
Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front. Immunol. 2019 May 21;10:1121.
Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015;125(12):1870–1876.
Kuehl WM, Bergsagel PL. Early Genetic Events Provide the Basis for a Clinical Classification of Multiple Myeloma. Hematology;2005(1):346–352.
Walker BA, Wardell CP, Johnson DC, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121(17):3413–3419.
Calame KL. Plasma cells: finding new light at the end of B cell development. Nat. Immunol. 2001;2(12):1103–1108.
Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood. 1998;91(8):2679–2688.
Kawano Y, Fujiwara S, Wada N, et al. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int. J. Oncol. 2012;41(3):876–884.
Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431–438.
Bataille R, Jego G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica. 2006;91:1234–40.
Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81(10):2658–2663.
Jeong T-D, Park C-J, Shim H, et al. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Korean J. Hematol. 2012;47(4):260–266.
Almeida J, Orfao A, Mateo G, et al. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Pathol. Biol. (Paris). 1999;47(2):119–127.
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418–5422.
Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–5417.
Kyle RA, Buadi FI, Rajkumar SVE. Management of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). Oncol. Williston Park N. 2011;25(7):578–586.
van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells. Cancer Res. 2018;78(10):2449–2456.
Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol. Oncol. Clin. North Am. 1992;6(2):273–284.
Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009;23(3):435–441.
Oranger A, Carbone C, Izzo M, Grano M. Cellular Mechanisms of Multiple Myeloma Bone Disease. Clin. Dev. Immunol. 2013;2013:1–11.
McSheehy PM, Chambers TJ. Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption. Endocrinology. 1986;119(4):1654–1659.
Balto K, Sasaki H, Stashenko P. Interleukin-6 Deficiency Increases Inflammatory Bone Destruction. Infect. Immun. 2001;69(2):744–750.
Gadó K, Domján G, Hegyesi H, Falus A. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Cell Biol. Int. 2000;24(4):195–209.
Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15(6):457–475.
Raje NS, Bhatta S, Terpos E. Role of the RANK/RANKL Pathway in Multiple Myeloma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2019;25(1):12–20.
Harmer D, Falank C, Reagan MR. Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma. Front. Endocrinol. 2018;9:788.
Kassen D, Lath D, Lach A, et al. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. Br. J. Haematol. 2016;172(1):64–79.
Sfiridaki K, Pappa CA, Tsirakis G, et al. Angiogenesis-Related Cytokines, RANKL, and Osteoprotegerin in Multiple Myeloma Patients in relation to Clinical Features and Response to Treatment. Mediators Inflamm. 2011;867576:
Jakob C, Goerke A, Terpos E, et al. Serum levels of total-RANKL in multiple myeloma. Clin. Lymphoma Myeloma. 2009;9(6):430–435.
Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102(3):1064–1069.
Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp. Hematol. 2013;41(4):387-397.e1.
Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. 2011;2011:765624.
Kwan Tat S, Padrines M, Théoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004;15(1):49–60.
Prideaux SM, Conway O’Brien E, Chevassut TJ. The Genetic Architecture of Multiple Myeloma. Adv. Hematol. 2014;2014:1–16.
Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J. Clin. Invest. 2012;122(10):3456–3463.
Fonseca R, Oken MM, Harrington D, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15(6):981–986.
Onodera N, McCabe N, Rubin C. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia [see comments]. Blood. 1992;80(1):203–208.
Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12(6):960–969.
Dewald GW, Kyle RA, Hicks GA, Greipp PR. The Clinical Significance of Cytogenetic Studies in 100 Patients With Multiple Myeloma, Plasma Cell Leukemia, or Amyloidosis. Blood. 1985;66(2):380–390.
Chng WJ, Kumar S, VanWier S, et al. Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Res. 2007;67(7):2982–2989.
Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2014;28(3):675–679.
Gutiérrez NC, Castellanos MV, Martín ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21(1):143–150.
Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J. Natl. Cancer Inst. - Monogr. 2008;(39):25–31.
Rasmussen T, Haaber J, Dahl IM, et al. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica. 2010;95(10):1730–1737.
Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K. Familial risks and temporal incidence trends of multiple myeloma. Eur. J. Cancer. 2006;42(11):1661–1670.
Broderick P, Chubb D, Johnson DC, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat. Genet. 2011;44(1):58–61.
Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349–355.
Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56-65.
Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–4575.
Nnonyelum ON, Anazoeze MJ, Eunice NO, et al. Multiple myeloma in Nigeria: a multi-centre epidemiological and biomedical study. Pan Afr. Med. J. 2015;22:292.
Baker A, Braggio E, Jacobus S, et al. Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood. 2013;121(16):3147–3152.
Fonseca R. Many and multiple myeloma(s). Leukemia. 2003;17(10):1943–1944.
Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99(10):3735–3741.
Palumbo A, Anderson K. Multiple Myeloma. 2011 Mar 17;364(11):1046-60.
Vincent Rajkumar S. Multiple Myeloma. Curr. Probl. Cancer. 2009;33(1):7–64.
Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–2972.
Jf SM, Mv M, E O, R G-S. Multiple myeloma: treatment evolution. Hematol. Amst. Neth. 2012;17 Suppl 1:S3-6.
V P, T J, P L, et al. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Cochrane Database Syst. Rev. 2019;2019(11).
Leich E, Weißbach S, Klein H-U, et al. Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. Blood Cancer J. 2013;3(2):e102–e102.
Hameed A, Brady JJ, Dowling P, Clynes M, O’Gorman P. Bone Disease in Multiple Myeloma: Pathophysiology and Management. Cancer Growth Metastasis. 2014;7:33–42.
Hill PA. Bone remodelling. Br. J. Orthod. 1998;25(2):101–107.
Papadopoulou EC, Batzios SP, Dimitriadou M, Perifanis V, Garipidou V. Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. Hippokratia. 2010;14(2):76–81.
Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood. 2006;108(13):3992–3996.
Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1989;7(12):1909–1914.
Roodman GD. Novel targets for myeloma bone disease. Expert Opin. Ther. Targets. 2008;12(11):1377–1387.
Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol. 2002;116(2):278–290.
Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp. Hematol. 2004;32(8):685–691.
Terpos E, Dimopoulos M-A. Myeloma bone disease: pathophysiology and management. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2005;16(8):1223–1231.
Andrews SW, Kabrah S, May JE, Donaldson C, Morse HR. Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br. J. Biomed. Sci. 2013;70(3):110–120.
De la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J. Clin. Invest. 1995;95(6):2846–2852.
Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 2002;100(13):4615–4621.
Lee JW, Chung HY, Ehrlich LA, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 2004;103(6):2308–2315.
Tai Y-T, Li X-F, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66(13):6675– 6682.
Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest. 1991;88(1):62–66.
Qiang Y-W, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood. 2008;112(1):196–207.
Ehrlich LA, Chung HY, Ghobrial I, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005;106(4):1407–1414.
Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005;106(7):2472–2483.
Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet Lond. Engl. 2010;376(9757):1989–1999.
Abstract View: 32 times
PDF Download: 11 times